Xigduo (dapagliflozin + metformin): first SGLT2 inhibitor combination tablet

Xigduo (dapagliflozin + metformin) has been launched for the treatment of type II diabetes.

The initial dose of Xigduo (dapagliflozin + metformin) should correspond to the patient's current metfomin dose
The initial dose of Xigduo (dapagliflozin + metformin) should correspond to the patient's current metfomin dose

The twice-daily combination tablet, launched by Bristol-Myers Squibb and AstraZeneca, contains the sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, and the biguanide, metformin.

Xigduo is licensed for use alongside diet and exercise to treat type II diabetes in adults who are inadequately controlled on metformin alone, inadequately controlled on other hypoglycaemic agents (including insulin) plus metformin, or currently taking the combination as separate tablets.

Xigduo is given as a single tablet twice daily and is available in two strengths: dapagliflozin 5mg/metformin 850mg and dapagliflozin 5mg/metformin 1g. Prescribers should select the initial dose of Xigduo based on the patient's current metformin dose. 

If Xigduo is to be added to a regimen containing insulin or a sulfonylurea, prescribers should consider reducing the dose of insulin and/or sulfonylurea to reduce the risk of hypoglycaemia.

View Xigduo drug record

Further information: BMS/AstraZeneca

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more